PARIS – A broken alarm system made it as easy as 1-2-3: A masked intruder clipped a padlock, smashed a window and stole a Picasso, a Matisse and three other masterpieces from a Paris museum Thursday — a $123 million haul that is one of the world's biggest art heists.
Offloading the artwork may prove a tougher task, however, with Interpol and collectors worldwide now on high alert.
In what seemed like an art thief's fantasy, the alarm system had been broken since March in parts of the Paris Museum of Modern Art, according to the city's mayor, Bertrand Delanoe.
The museum, in a tony neighborhood across the Seine River from the Eiffel Tower, reopened in 2006 after spending $18 million (euro15 million) and two years upgrading its security system. Spare parts had been ordered to fix the alarm but had not yet arrived, the mayor said in a statement.
So with no alarm to worry about, a lone masked intruder entered the museum about 3:50 a.m., said Christophe Girard, deputy culture secretary at Paris City Hall. The thief cut a padlock on a gate, then broke a side window and climbed inside — his movements caught on one of the museum's functioning cameras, according to the Paris prosecutor's office.
The intruder later slipped back out, carrying the canvases and leaving behind empty frames. The whole thing took 15 minutes, a police official said.
Three security guards were on duty overnight, but "they saw nothing," Girard said. A night watchman discovered the theft around 7 a.m.
The stolen works included Pablo Picasso's "Le pigeon aux petits-pois" (The Pigeon with the Peas), an ochre-toned Cubist oil painting worth an estimated $28 million (euro23 million), and "La Pastorale" (Pastoral), a pastel-hued oil painting of nudes on a hillside by Henri Matisse worth about $17.5 million (euro15 million), Girard said.
Also seized were "La femme a l'eventail" (Woman with a Fan) by Amedeo Modigliani, "L'olivier pres de l'Estaque" (Olive Tree near Estaque) by Georges Braque and "Nature morte aux chandeliers" (Still Life with Chandeliers) by Fernand Leger.
Estimates of the total value of the paintings varied: The prosecutor's office initially put their worth as high as $613 million (euro500 million) but later downgraded the figure to about $111 million (euro90 million). Girard said the total value was about $123 million (euro100 million).
The broken alarm system also renewed concerns about museum security in the French capital. There was no operating surveillance system when a thief made off with a red sketchbook of 33 Picasso drawings from the nearby Picasso Museum while it was undergoing renovations last summer.
Within hours of Thursday's heist, red-and-white tape surrounded the Museum of Modern Art and signs on the Art Deco building's ornate bronze doors said it was closed for "technical reasons."
On a cordoned-off balcony, police wearing blue gloves and face masks examined the museum's broken window and the discarded frames. The paintings appeared to have been carefully removed from the disassembled frames, not sliced out.
Investigators were trying to determine whether the intruder was operating alone, Girard told reporters. Stephane Thefo, a specialist at Interpol who handles international art theft investigations, expressed doubt that one person could have pulled it off the heist, even if only one person was caught on camera.
Many high-profile art thefts have ended in failure, with the artworks recovered as thieves struggle to trade their illegal bounty for cash. But some famous stolen works remain at large — such as those seized more than two decades ago from Boston's Isabella Stewart Gardner Museum.
Alice Farren-Bradley of the Art Loss Registry in London said the Paris theft appeared to be one of the biggest art heists ever, considering the prominence of the artists, the value of the paintings and the high profile of the museum.
However, she said it will be "virtually impossible" to sell such prominent paintings on the open market and typically stolen art fetches lower prices on the black market.
"Very often they can be used as collateral to broker other deals" involving drugs or weapons, she said. "They are not necessarily going to be bought by some great lover of the arts."
Art expert Jean-Marie Baron said the heist could have been organized by thieves who plan to sell the paintings to wealthy individuals in Russia, China or elsewhere, and "who won't verify the origins of the paintings." Another possibility was that the thieves planned to "ransom" the paintings in exchange for a big insurance payout, he said.
The FBI estimates the market for stolen art at $6 billion. The Art Loss Register has tallied up to 170,000 pieces of stolen, missing and looted art and valuables.
Picasso is the world's most stolen artist due to his prolific output and the value of his works. The Art Loss Register lists some 550 missing Picasso pieces, including paintings, lithographs, drawings and ceramics, as of 2007.
Hours after Thursday's heist, the director of the neighboring Palais de Tokyo modern art museum called the thieves "imbeciles."
"Those paintings are absolutely unsellable. First off because these are very well known paintings. And also because we are in a new civilization ... of instant global communication," Pierre Cornette de Saint-Cyr told AP Television News. "The entire planet has pictures of these paintings."
The loss is "like the death of a family member," lamented Flemming Friborg, manager of Copenhagen's Glyptotek museum, known for its Impressionist collection.
null
bored
Thursday, May 20, 2010
Friday, May 14, 2010
NBC CANCELS the Tv show heros WITHOUT A SEASON FINALE!
NBC Cancels Once-Mighty Heroes
By Natalie Abrams
Fri May 14, 3:19 PM PDT
After four seasons on NBC, Heroes has been canceled, according to The Hollywood Reporter.
Fall 2010 TV Scorecard: Which shows are returning? Which aren't?
The super-series averaged less than 5 million viewers in its latest season. The network had considered giving the Tim Kring-produced drama a few more episodes to wrap up storylines, but the cost of the show and NBC's expanding fall slate led to Heroes' cancelation.
Report: NBC likely to cancel Heroes
Law & Order, Trauma and Mercy were also canceled by the network, which has already ordered 11 new series for the fall, including J.J. Abrams' Undercovers and Jerry Bruckheimer's Chase.
NBC cancels Law & Order, picks up SVU and Law & Order: Los Angeles
Reps for the NBC series declined TVGuide.com's request for comment
By Natalie Abrams
Fri May 14, 3:19 PM PDT
After four seasons on NBC, Heroes has been canceled, according to The Hollywood Reporter.
Fall 2010 TV Scorecard: Which shows are returning? Which aren't?
The super-series averaged less than 5 million viewers in its latest season. The network had considered giving the Tim Kring-produced drama a few more episodes to wrap up storylines, but the cost of the show and NBC's expanding fall slate led to Heroes' cancelation.
Report: NBC likely to cancel Heroes
Law & Order, Trauma and Mercy were also canceled by the network, which has already ordered 11 new series for the fall, including J.J. Abrams' Undercovers and Jerry Bruckheimer's Chase.
NBC cancels Law & Order, picks up SVU and Law & Order: Los Angeles
Reps for the NBC series declined TVGuide.com's request for comment
Monday, May 10, 2010
TWITTER CRASHES-EVERYONE NOW HAS 0 FOLLOWERS 0 FOLLOWING
BUT FOUND A VIRUS IN THERE SOFTWARE THIS IS THE MESSAGE THEY SENT OUT
Follow bug discovered, remedied. 21 minutes ago
We identified and resolved a bug that permitted a user to “force” other users to follow them. We’re now working to rollback all abuse of the bug that took place. Follower/following numbers are currently at 0; we’re aware and this too should shortly be resolved.
Update (10:18 AM PST): Of note: protected updates did not become public as a result of this bug.
Follow bug discovered, remedied. 21 minutes ago
We identified and resolved a bug that permitted a user to “force” other users to follow them. We’re now working to rollback all abuse of the bug that took place. Follower/following numbers are currently at 0; we’re aware and this too should shortly be resolved.
Update (10:18 AM PST): Of note: protected updates did not become public as a result of this bug.
Tuesday, May 4, 2010
Thursday, April 29, 2010
FDA approves breakthrough cancer therapy Provenge
WASHINGTON - A first-of-a-kind prostate cancer treatment that uses the body's immune system to fight the disease received federal approval Thursday, offering an important alternative to more taxing treatments like chemotherapy. Dendreon Corp.'s Provenge vaccine trains the immune system to fight tumors. It's called a "vaccine" even though it treats disease rather than prevents it.
Doctors have been trying to develop such a therapy for decades, and Provenge is the first to win approval from the Food and Drug Administration.
"The big news here is that this is the first immunotherapy to win approval, and I suspect within five to ten years immunotherapies will be a big part of cancer therapy in general," said Dr. Phil Kantoff, an oncologist at the Dana-Farber Cancer Institute who helped run the studies of Provenge.
Experimental vaccines to treat other cancers — including the deadly skin disease melanoma and an often fatal childhood tumor called neuroblastoma — are already in late-stage development.
Currently doctors treat cancer by surgically removing tumors, attacking them with chemotherapy drugs or blasting them with radiation. Provenge offers an important fourth approach by directing the body's natural defense mechanisms against the disease.
The treatment is intended for prostate cancer that has spread elsewhere in the body and is not responding to hormone therapy.
Medical specialists hailed the approval as an important milestone, but stressed it will serve as an addition to current medical practice, not a replacement.
"This is just one step in a new pathway for treating patients," said Dr. Simon Hall, chairman of urology at Mt. Sinai Hospital. "We have to make them realize this isn't a cure, it's very variable."
Company studies showed that taking Provenge added four months to the lives of men with advanced prostate cancer.
That may not sound like a lot, but it is longer than the three months afforded by Taxotere, the only chemotherapy approved for men in this situation. Doctors hope for even greater benefit if they give the drug earlier in the course of the disease.
Dendreon said Thursday the drug will cost $93,000 per patient.
The approval marks a remarkable turnaround for Seattle-based Dendreon, whose shares plummeted three years ago when the FDA delayed a decision on the therapy, asking for more proof of safety and effectiveness. That delay came despite an expert panel's recommendation for approval.
Dendreon shares jumped 19 percent to new highs ahead of the news, rising to an all-time high of $47.32. The company spent more than 15 years developing and testing Provenge.
Analysts expect the product to reach blockbuster sales status — over $1 billion — by 2016, as the company expands production capacity.
Each regimen of Provenge must to tailored to the immune system of the patient using a time-consuming formulation process.
Doctors collect special blood cells from each patient that help the immune system recognize cancer as a threat. The cells are mixed with a protein found on most prostate cancer cells and another substance to rev up the immune system. The resulting "vaccine" is given back to the patient as three infusions two weeks apart.
Initially, Dendreon will identify Provenge patients through the 50 medical centers that helped test the drug. But researchers have been told the company will only be able to provide vaccines for a few patients at each site per month.
"There are going to be a lot of patients that want it and there will be limited resources as they are getting this up and running," said Dr. Deborah Bradley of Duke University School of Medicine
About 192,000 new cases of prostate cancer were diagnosed in 2009, and 27,000 men died of the disease, according to the FDA. Prostate cancer most often affects older men.
Side effects of Provenge are relatively mild, such as chills, fatigue, fever, and headache. By comparison, side effects of chemotherapy typically include hair loss, nausea, anemia and diarrhea.
By MATTHEW PERRONE,
___
AP Business Writer Marley Seaman contributed to this story from New York
Doctors have been trying to develop such a therapy for decades, and Provenge is the first to win approval from the Food and Drug Administration.
"The big news here is that this is the first immunotherapy to win approval, and I suspect within five to ten years immunotherapies will be a big part of cancer therapy in general," said Dr. Phil Kantoff, an oncologist at the Dana-Farber Cancer Institute who helped run the studies of Provenge.
Experimental vaccines to treat other cancers — including the deadly skin disease melanoma and an often fatal childhood tumor called neuroblastoma — are already in late-stage development.
Currently doctors treat cancer by surgically removing tumors, attacking them with chemotherapy drugs or blasting them with radiation. Provenge offers an important fourth approach by directing the body's natural defense mechanisms against the disease.
The treatment is intended for prostate cancer that has spread elsewhere in the body and is not responding to hormone therapy.
Medical specialists hailed the approval as an important milestone, but stressed it will serve as an addition to current medical practice, not a replacement.
"This is just one step in a new pathway for treating patients," said Dr. Simon Hall, chairman of urology at Mt. Sinai Hospital. "We have to make them realize this isn't a cure, it's very variable."
Company studies showed that taking Provenge added four months to the lives of men with advanced prostate cancer.
That may not sound like a lot, but it is longer than the three months afforded by Taxotere, the only chemotherapy approved for men in this situation. Doctors hope for even greater benefit if they give the drug earlier in the course of the disease.
Dendreon said Thursday the drug will cost $93,000 per patient.
The approval marks a remarkable turnaround for Seattle-based Dendreon, whose shares plummeted three years ago when the FDA delayed a decision on the therapy, asking for more proof of safety and effectiveness. That delay came despite an expert panel's recommendation for approval.
Dendreon shares jumped 19 percent to new highs ahead of the news, rising to an all-time high of $47.32. The company spent more than 15 years developing and testing Provenge.
Analysts expect the product to reach blockbuster sales status — over $1 billion — by 2016, as the company expands production capacity.
Each regimen of Provenge must to tailored to the immune system of the patient using a time-consuming formulation process.
Doctors collect special blood cells from each patient that help the immune system recognize cancer as a threat. The cells are mixed with a protein found on most prostate cancer cells and another substance to rev up the immune system. The resulting "vaccine" is given back to the patient as three infusions two weeks apart.
Initially, Dendreon will identify Provenge patients through the 50 medical centers that helped test the drug. But researchers have been told the company will only be able to provide vaccines for a few patients at each site per month.
"There are going to be a lot of patients that want it and there will be limited resources as they are getting this up and running," said Dr. Deborah Bradley of Duke University School of Medicine
About 192,000 new cases of prostate cancer were diagnosed in 2009, and 27,000 men died of the disease, according to the FDA. Prostate cancer most often affects older men.
Side effects of Provenge are relatively mild, such as chills, fatigue, fever, and headache. By comparison, side effects of chemotherapy typically include hair loss, nausea, anemia and diarrhea.
By MATTHEW PERRONE,
___
AP Business Writer Marley Seaman contributed to this story from New York
Saturday, April 17, 2010
Jay z and Beyonce Performs in COACHELLA together!
LOVED IT!
Grace Jones Speaks On Lady Gaga

Grace Jones To Lady Gaga: You're a Copycat
Saturday, April 17, 2010 | 4:30 PM
by Yolanda Sangweni
What's not to love about Grace Jones? She's fierce, original and tells it like it is. Pop music's original diva of the night recently took on Lady Gaga in an interview with the Guardian newspaper. Asked how she felt about Gaga, Jones responded: "I really don't think of her at all. I go about my business."
And what of accusations that Gaga had taken her style? "Well, you know, I've seen some things she's worn that I've worn, and that does kind of piss me off." Has Gaga asked her to collaborate? "Yes, she did, but I said no," Jones responded. "I'd just prefer to work with someone who is more original and someone who is not copying me, actually."
Ouch. Jones is not the first artist to have some words for Gaga of late. "Paper Planes" singer M.I.A. recently called Gaga out on her music, saying it wasn't as "weird" as she'd like us to believe. "She models herself on Grace Jones and Madonna, but the music sounds like 20-year-old Ibiza music, you know? She's not progressive, but she's good mimic."
India.Arie also had some issues with Gaga and took to Twitter to discuss the "unspoken back story" of the video for "Telephone" co-starring Beyonce. "Crazy to me that the Dark, underbelly, shock at all cost thing is a trend," Arie tweeted.
Can we really talk about any artist being "authentic" or "original" in the age of sampling? Admittedly, no other artists have brought avant-garde high-concept fashion to pop music quite like Jones and Gaga in the pst two decade. But let's face it, there is a fundamental difference between being influenced by someone and mimicking them. If Jones is calling Gaga out for wearing the same outfits, then call us petty, but we have a problem because we know when it comes to miss Jones it's all about R-E-S-P-E-C-T.
Read more: http://www.essence.com/entertainment/hot_topics/grace_jones_lady_gaga_copycat.php#ixzz0lPOvv3hM
Friday, April 16, 2010
Que From Day 26 Feeling Freaky on Freaky Fridays

damn bro you didnt have no groupies to help u out this morning...i feel you on riding solo thou LMAO!
AND JUST IN CASE YOU MISSED WILLIES FROM DAY 26 HERES HIS
Thursday, April 1, 2010
Nicki Minaj first Music Video "Massive Attack"
I LIKE IT BUT ITS ONLY ONE LIL KIM NICKI!!
Subscribe to:
Posts (Atom)

